Published in final edited form as:

Expert Opin Drug Discov. 2012 September ; 7(9): 849–859. doi:10.1517/17460441.2012.711312.

New Hepatitis C Virus Drug Discovery Strategies and Model Systems

Snawar Hussain, Naina Barretto, and Susan L Uprichard

University of Illinois at Chicago, Department of Medicine, Chicago, IL, USA

Abstract

Introduction—Hepatitis C virus is a major cause of liver disease worldwide and the leading indication for liver transplantation in the United States. Current treatment options are expensive, not effective in all patients and are associated with serious side effects. While pre-clinical anti-HCV drug screening is still hampered by the lack of readily infectable small animal models, the development of cell culture HCV experimental model systems has driven a promising new wave of HCV antiviral drug discovery.

Areas covered—This review contains a concise overview of current HCV treatment options and limitations with a subsequent in-depth focus on the available experimental models and novel strategies that have and continue to enable important advances in HCV drug development.

Expert opinion—With a large cohort of chronically HCV infected patients progressively developing liver disease that puts them at risk for hepatocellular carcinoma and hepatic decompensation, there is an urgent need to develop effective therapeutics that are well-tolerated and effective in all patients and against all HCV genotypes. Significant advances in HCV experimental model development have expedited drug discovery; however, additional progress is needed. Importantly, the current trends and momentum in the field suggests that we will continue to overcome critical experimental challenges to reach this end goal.

Keywords

Hepatitis C Virus (HCV); Experimental model systems; Antivirals; Replicons; HCV pseudoparticles (HCVpp); High throughput Screening (HTS)

1 Introduction

Approximately 170 million people or 3% of the world population, are chronically infected with hepatitis C virus (HCV)¹. While new infection rates are difficult to determine, it is estimated that in 70–80% of infections, the virus is able to elude the host immune response and establish a chronic infection^{1, 2}. The rate of disease progression in infected individuals is variable and many remain asymptomatic for 10–30 years; however, without therapeutic intervention chronic infection can lead to end-stage liver disease including steatosis, fibrosis, cirrhosis, and hepatocellular carcinoma^{2, 3}. As a result, in Europe and the United States, HCV is the most common cause of chronic infectious liver disease with HCV infection in the United States alone causing 8000–10,000 deaths annually^{4, 5}.

2 Current HCV treatment and obstacles

In the absence of a protective vaccine, combination therapy with pegylated interferon alpha (PEG-IFN α) and ribavirin (RBV) has been the mainstay of HCV treatment for a decade. Although PEG-IFN α /RBV combination therapy has been effective in up to 80% of HCV genotype 2 or 3 infected patients monitored in studies, sustained virological response (SVR)

rates are much lower in patients with HCV genotype 1 and 4 infections (reviewed in ^{6, 7}). Success rates are also lower in particular patient populations such as African Americans as well as patients with high HCV RNA levels, high body mass index, advanced liver disease, and those co-infected with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) (reviewed in ⁷). Notably, in 2011 two HCV NS3/4A protease inhibitors, Telaprevir and Boceprevir, were FDA-approved for use in combination with PEG-IFN α /RBV for patients infected with HCV genotype 1 because studies revealed that triple therapy in treatment-naïve patients increase SVR from ~ 40% to 70% or more (reviewed in ^{6, 7}).

While there are still limitations associated with Telaprevir and Boceprevir, the recent advances in HCV molecular biology discussed below continue to facilitate the development of additional specifically-targeted HCV antivirals, directed against viral proteins as well as the viral-host interactions upon which successful infection is dependent. Development of additional HCV antiviral agents is critical for identifying therapeutics that are broadly effective against all the major HCV genotypes. Additionally, it will allow for effective treatment combination strategies to prevent the emergence of drug resistant viral escape mutations, a concern that arises when RNA viruses are treated with compounds that directly target viral proteins and/or specific host interactions. Co-administration of PEG-IFN α /RBV has proven relatively effective at preventing rapid viral escape from Telaprevir and Boceprevir, but due to the limited efficacy and side effects of IFN, the goal is to eventually eliminate the use of IFN when sufficient direct-acting antivirals are clinically available.

3 Hepatitis C virus biology

HCV is an enveloped, positive-strand RNA virus belonging to family Flaviviridae. The viral genome consists of a single uncapped RNA of approximately 9600 nucleotides containing one large open-reading frame, flanked by highly structured 5' and 3'-nontranslated regions (NTRs) which play regulatory roles in cap-independent translation of the viral proteins and viral RNA genome replication^{8, 9}. The HCV virion consists of the genomic RNA encased in a nucleocapsid formed by the core protein, surrounded by a lipid bilayer containing the viral E1/E2 glycoproteins¹⁰. These virions exist in the serum of patients associated with triglyceride-enriched low density lipoproteins (LDL) and very low density lipoproteins (VLDL)^{11, 12} and thus exhibit a wide range of densities with the more lipid-enriched, lower density particles tending to have the highest infectivity^{13–15}. HCV viral entry into cells requires sequential interaction between virion components and cellular factors^{16, 17}. The receptor engagement as well as acidic pH of endosome triggers the fusion of the virus envelope and endosomal membrane, leading to release of the viral genome into the cytoplasm^{15, 18–22}. In the cytoplasm, internal ribosome entry site (IRES)-dependent translation of the viral RNA by the host cell translation machinery produces a single polypeptide of ~3000 amino acid, which is co- and post-translationally cleaved by cellular and viral proteases to yield at least 10 mature viral proteins (Core-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B)²³. Based on the functional HCV replicon system, it has been demonstrated that NS3-NS5B are essential for viral RNA replication²⁴. The replication complex uses the viral genome as template to generate negative-strand viral RNA intermediates, which in turn are used to synthesize new positive-strand genomic RNA. The synthesized HCV genomic RNA then in theory can serve as template for translation of more viral protein, as template for replication by the NS5B polymerase, or be encapsidated to produce progeny virus²⁵. After encapsidating a viral genome, newly formed nucleocapsids acquire their envelop by budding through the ER membrane containing envelope glycoproteins and are secreted from the cell through exocytosis⁹. Differences in the density of intracellular assembled virion particles compared to extracellular secreted virion particles are consistent with post-assembly lipidation of virion particles during and/or after secretion through ER/post-ER compartment²⁶. Secretion of infectious HCV particles is influenced by

components of the VLDL pathways such as microsomal triglyceride transfer protein (MTP), apolipoprotein B (ApoB) and apolipoprotein E (ApoE)^{11, 12, 27} suggesting that HCV uses the cellular lipoprotein/cholesterol export system.

4 HCV drug discovery: Experimental model systems

4.1 Biochemical assays

The successful cloning of HCV in 1989²⁸ provided the first insight into the viral genome as well as the ability to express and characterize the viral proteins, which made the development of conventional biochemical assays feasible. Biochemical assays using purified protein and defined buffers can be quite useful for elucidating the mechanistic requirements of enzyme function (e.g. substrate specificity, co-factor requirements, etc...) and for identifying direct-acting small molecule inhibitors. Hence, early HCV drug discovery included these types of standard in vitro approaches. Using purified NS3 protein, fluorogenic, chromogenic and radioactive assays for NS3 protease and helicase activity were developed and used to analyze HCV NS3 activity and screen for potential inhibitors^{29–32}. However, biochemical assays designed to assess the enzymatic activity of purified HCV NS5B were more challenging (e.g. relatively low catalytic efficiency, low yield, controversial terminal nucleotidyl transferase activity, etc...)(reviewed in ^{33, 34}), which limited high throughput screening of NS5B inhibitors until HCV replicons became available in 1999^{35–37}. Some of these issues likely reflect that despite being extremely useful, biochemical assays can also be limited due to their inherent isolation away from the relevant host cell environment. Hence, even when biochemical approaches are successful, it is important to validate the outcome in more physiologically relevant systems that can additionally assess practical issues of cell-permeability and off-target effects etc.

4.2 Cell-based assays

The development of cell-based HCV assays was a major step forward in the arena of HCV drug development. At a minimum, cell-based HCV models for assessing the efficacy of specific antivirals depend on the existence of cell lines that support the viral activity under investigation and virus components/strains that can perform that activity in cell culture. These tools have not always been readily available for HCV research perhaps because HCV primarily infects fully differentiated hepatocytes, a cellular phenotype not maintained when these cells are removed from their in vivo environment. As a result, HCV historically has not grown well in cell culture and therefore several surrogate model systems such as stable transfection of partial or full length HCV genomes (replicons)²⁴ and pseudotyped retroviral particles (HCVpp)^{21, 38, 39} were developed. While these simple and robust systems are still used extensively to investigate specific aspects of HCV biology and assess HCV inhibitors, in 2005 an infectious HCV cell culture system supporting the entire HCV life cycle also finally became available^{13, 40, 41}. The advantages and limitations of these various experimental systems are discussed below.

4.2.1 HCV replicons—While the cloning of HCV allowed for the classification of the HCV into a reasonably well understood family of related viruses, specific understanding of HCV replication remained elusive for more than a decade until the development of the HCV replicon system²⁴, which recapitulates the intracellular steps of HCV RNA replication. The first replicons were self-replicating recombinant viral RNA in which the viral structural genes were replaced with the neomycin phosphotransferase (*Neo*) selection marker²⁴. The *Neo* gene is translated from HCV IRES located in the HCV 5'NTR, whereas the HCV non-structural proteins (NS3–NS5B) are translated from an inserted encephalomyocarditis virus (ECMV) IRES. Because the encoded viral proteins are able to replicate the template replicon RNA from which they are expressed, cells that support replicon replication

maintain high levels of the replicon RNA and can be selected based on their constitutive *Neo* expression. These cells can then be expanded to create HCV replicon cell lines, which serve as a model of autonomous HCV replication.

The HCV replicon system has proven to be very useful for HCV drug discovery efforts. Not only did the replicon system provide an HCV-specific, robust assay to screen for HCV NS5B polymerase inhibitors, but it allowed for the first time non-target-specific screens that could identify inhibitors of HCV replication that interfered with any aspect of replication, i.e. viral or host factors (e.g. Cyclophilin A). The ability to create non-infectious replicon systems from multiple different HCV genotypes also is advantageous in terms of assessing whether an inhibitor is broadly effective against multiple HCV genotypes. Some of the more widely used replicons reported to date include numerous genotype 1b replicons (e.g. Con1, HCV-N), the H77 clone genotype 1a replicon and the JFH-1 clone genotype 2a replicon^{24, 42–48}. While cell line restriction is still a limitation of the more recently established cell culture HCV infection system, another advantage of the replicon system is that replication has been established in multiple liver derived cell lines (e.g. HepG2 and Huh6) as well as non-liver cell lines (e.g. 293 and HeLa) and rodent cell lines (e.g. NIH3T3, AML12, MMHD3)^{49–53}.

The most obvious limitation of the replicon system is that it cannot be used to study the entire HCV infection process, particularly the early steps of virus life cycle before viral replication (e.g. viral attachment, entry and un-coating) or the late steps of viral infection after genome replication (e.g. virion assembly, maturation and release). Additionally, in some cases caution may be warranted because all replicons, except for the genotype 2a JFH-1 clone, contain cell culture adaptive mutations which when introduced back into viral genome, render it non-infectious in chimpanzees⁵⁴. Hence, like many in vitro viral systems, HCV replicons may not accurately mimic which viral-host interactions are most critical in vivo.

4.2.2 HCV pseudotyped particles—A relatively convenient approach to study the entry of enveloped viruses is the use of pseudotyped retroviral particles harboring the envelope glycoproteins of the virus of interest. HCV pseudoparticles (HCVpp) were first generated in 2003^{21, 38}. Analogous to other viral pseudotyped particles, this was accomplished in 293 cells by co-transfecting a plasmid encoding an envelope deficient, packaging competent retroviral genome [Moloney Murine Leukemia Virus (MMLV) or HIV] engineered to express a reporter gene (e.g. GFP or Luciferase) along with a plasmid encoding E1/E2 envelope glycoproteins of HCV. Entry of the recombinant viral particles into cells is then dictated by the envelope glycoproteins and efficiency of the entry process can be measured by a simple reporter gene assay. Importantly, functional analyses by many research groups have demonstrated that the requirements for HCVpp cell entry closely mimic HCV entry in terms of antibody neutralization. Therefore, it has proven to be a useful method to study the entry of various HCV genotypes, the cellular factors required for HCV entry, and the tropism restrictions associated with HCV entry^{39, 55–58}. As such, HCVpp systems are safe, robust and easy to manipulate for drug discovery efforts focused on specific steps of the viral entry process. As a result, HCVpp systems have been used to screen libraries of small molecule inhibitors and several promising entry inhibitors are in early clinical testing^{59–62}. One caveat; however, is that these particles are not identical to authentic HCV particles in terms of lipid composition and this does result in some functional differences in entry factor requirements and kinetics. For example, the LDL receptor and the Niemann Pick C1 Like-1 (NPC1L1) cholesterol uptake receptor are required for the entry of infectious HCV particles such that HCV infection is blocked by antibodies or other small molecule inhibitors directed against these cell surface proteins; however, HCVpp entry is much faster and independent of these two factors^{17, 21, 38, 63}. It would be interesting to test whether the production of

HCVpp in VLDL-synthesizing cells might lead to the assembly of lipoprotein-associated HCVpp, but the envelopment of retroviral particles at the plasma membrane compared to the natural maturation of HCV particles through the ER/Golgi might prevent the association of HCVpp with lipoproteins regardless of producer cell type.

4.2.3 HCV cell culture infection system—The advance that finally allowed for the study and screening of all aspects of the viral life cycle is the HCV cell culture (HCVcc) infection system. The HCVcc infection system was made possible by the identification of the HCV genotype 2a isolate, JFH-1, which was cloned from a Japanese patient suffering from fulminant hepatitis⁶⁴. This HCV clone is unique because replicons derived from this consensus genome did not require “infection-limiting” adaptive mutations in order to replicate efficiently in cell culture⁴⁴. Based on this phenotype, the JFH-1 clone^{40, 41} and a chimeric genotype 2a derivative (J6/JFH-1)¹³ were tested and found to initiate productive infection in Huh7 human hepatoma cells. Specifically, electroporation of in vitro transcribed genomic HCV RNA from this construct into Huh7 cells resulted in efficient replication and rapid spread of HCV to non-transfected cells. Additionally, filtered medium from the transfected cell culture was able to transmit infection to naïve cell cultures indicating the presence of secreted infectious virus particles. Cell culture produced virus was confirmed to be infectious in chimpanzees⁴¹ and in chimeric SCID-uPA mice transplanted with primary human hepatocytes (discussed in section 4.3)⁶⁵. Likewise virus recovered from infected mice was infectious in Huh7 cells in vitro⁶⁵. Cell culture produced virus is antigenically similar to HCV clinical isolates as it can be neutralized by anti-CD81 antibodies, as well as by antibodies isolated from chronically HCV infected patients^{40, 41, 66} and it demonstrates similar sensitivity to antivirals that directly target the viral proteins^{13, 40, 41, 66}.

The obvious advantage of the HCVcc system is that it encompasses the complete viral life cycle and allows for production and analysis of infectious HCV particles. It also offers additional experimental flexibility in terms of time of inhibitor treatment relative to viral inoculation, the ability to alter viral dose, and the opportunity to measure multiple different viral parameters (i.e protein expression, replication, infectious virus production, etc.), which allows for more informative screens tailored to specific questions. However, in line with the historically slow progress in the HCV research field, six years since the development of the HCVcc system, there are still major drawbacks to the system in terms of drug development. A continuing technical challenge is that even under ideal conditions HCVcc grows to relative low titers making typical high multiplicity of infection (MOI) drug screening approaches less feasible. Low MOI longer term assays have been successfully established (discussed below), but these by nature are more challenging, expensive, and prone to cell culture related variability. That being said, a more fundamental limitation of the system is its dependence on the HCV JFH-1 clone. Being restricted to a single viral clone is problematic because different HCV genotypes typically exhibit differential sensitivity towards individual antivirals, thus screening compounds against the available JFH-1 genotype 2a clone often identifies genotype-specific inhibitors that are less effective against other more clinically prevalent and challenging genotypes (Yu and Uprichard, unpublished data). To address this limitation, JFH-1 based chimeric viruses have been created by substituting discrete regions of different HCV genotype clones into a JFH-1 backbone^{67–71}. These chimeric viruses have proven quite useful in assessing the differences in viral entry among genotypes (i.e. chimeric viruses containing the structural region of different HCV genotypes fused to the non-structural region of the JFH-1 clone). However, in terms of drug discovery they are limited, as they often grow to lower titers and can only be used to study a limited aspect of the viral life cycle, which conceptually negates the major advantage of the infection system. While efforts are being made to propagate other HCV clones in Huh7 cells with varying success^{72–74}, another ongoing strategy is to develop more physiologically relevant hepatocyte cell culture systems that better mimic natural in vivo virus-host interactions⁷⁸.

This might allow for infection with other HCV genotypes as well as offer a better understanding of how HCV infection impacts normal hepatocyte function. Many groups have confirmed that primary human hepatocytes are permissive to different HCV genotypes and clinical isolates^{63, 75–77}, but these cells can be difficult to obtain and are notoriously difficult to maintain in cell culture. This limits their practical use for drug screening, though at least one group has managed to overcome the challenges and successfully have grown primary hepatocytes in a reasonably high throughput 96-well format⁷⁸.

4.3 HCV animal models

While typically large scale antiviral screening approaches begin in vitro, later stage drug discovery confirmation efforts are often performed in small animal model systems. However, in the case of HCV, the restricted species tropism of the virus has been a significant obstacle. Although chimpanzees are susceptible to HCV infection, their usage is limited due to ethical concerns including their endangered status, as well as their exceptionally high costs. Consequently, a main focus in the field has been the development of HCV mouse models⁷⁹.

To overcome the known and unknown species barriers that prevent HCV infection of mice, chimeric xenograft mouse models have been developed. The first and most commonly used model is based on severe combined immunodeficiency (SCID) mice carrying a lethal urokinase-type plasminogen activator (uPA) transgene expressed in their hepatocytes by the albumin promoter. While the endogenous hepatocytes in these mice are destined to die, these uPA-SCID mice can be rescued by transplantation with human hepatocytes which repopulate the liver. The human hepatocytes in these mice remain permissive to human hepatotropic viruses such as HBV and HCV^{80, 81}. These xenotransplanted mice are a great tool to assess the efficacy of HCV antivirals and several groups have demonstrated that in vivo HCV infection can be inhibited by blocking either the viral E1/E2 glycoproteins or one of the host cell HCV entry factors, as well as a variety of other known HCV inhibitors (e.g. interferon, NS3 protease inhibitors, etc.)^{17, 82–86}. While the use of this model is not widespread due to technical as well as physiological limitations of the system, chimeric mice with humanized livers are currently the most relevant small animal model for testing inhibitors of HCV infection in vivo.

Importantly, sensitive luciferase reporter strategies indicate that transgenic mice expressing the human HCV entry factors CD81, Occludin, scavenger receptor class B1 (SR-B1), and Claudin 1 are permissive for a low level of HCVcc entry⁸⁷. However, the inability to directly detect infection in these animals (i.e. HCV RNA and/or protein expression) suggests other blocks to infection exist and/or that additional factors are required for efficient infection of mice with HCV. Notably, Sainz et al., (2012) recently identified the cholesterol transporter NPC1L1, as factor required for infectious HCV entry¹⁷. Considering that NPC1L1 is expressed on hepatocytes only in humans and chimpanzees, it will be interesting to see if exogenous expression of human NPC1L1 on the hepatocytes of these mice will confer more robust permissiveness to infectious HCV entry. This combined with the recent demonstration that over expression of human miR122 significantly enhances HCV RNA replication in mouse cells⁸⁸ adds renewed hope that a mouse model of HCV infection may soon be a reality.

5 HCV drug discovery approaches and methodologies

5.1 Reporter viruses / cell lines

Some of the more interesting recent advances made in HCV drug discovery have been related to the development of novel strategies for simple yet sensitive detection of HCV in cell-based assays. RT-qPCR detection of the viral genome and ELISA-based detection of

viral antigen are two common ways for detecting HCV. However, by nature these assays are cumbersome and time consuming and thus not ideal for high throughput analysis. As replication-enhancing cell-culture adaptive mutations within different replicon clones were identified^{46, 89, 90} and cell lines more permissive for HCV replication were created⁹¹ the requirement for active selection was reduced and replicons expressing various reporter genes (e.g. GFP, beta-lactamase and luciferase) instead of selection markers were generated for more convenient mix-and-read high throughput monitoring of replicon replication^{42, 92–96}. Similar approaches have also been used by inserting analogous reporter genes into the full length HCVcc genome^{70, 97–100}. While, in theory, such modified viruses are better suited for high throughput screening, insertion of foreign genes into viral genome often results in reduced viral replication, therefore to facilitate the rapid detection of HCV infection without compromising the replication efficiency of the virus, an alternate approach has been to develop reporter cell lines that transmit a detectable signal in response to HCV infection. One example is a cell line engineered by Iro et al. (2009), which releases secreted alkaline phosphatase (SEAP) into the culture media upon infection¹⁰¹. To accomplish this, cells were designed to constitutively express an EGFP-SEAP fusion protein, in which EGFP is fused to SEAP via a linker region that contains the recognition sequence of the HCV NS3/4A protease. Upon HCV infection, the viral NS3/4A cleaves the linker region and releases SEAP from the fusion protein, triggering secretion into the extracellular culture medium. Using an analogous strategy Chockalingam et al. generated a cell line in which HCV infection can be detected via cell death^{102, 103}. These cells express an NS3-cleavable derivative of the proapoptotic factor Bid (mBid) that can be activated by HCV infection. As such, HCV infection induces a pronounced cytopathic effect and anti-HCV compounds can be identified by their ability to prevent mBid-mediated cell death. To monitor HCV infection on a single cell level, Jones et al, created a stable Huh7 cell line expressing a fluorescent protein with a nuclear localization signal (NLS) fused to the mitochondrial bound IPS protein (e.g. RFP-NLS-IPS)¹⁰⁴. In uninfected cells, this mitochondrial tethered fusion protein exhibits a punctate cytosolic localization pattern. However because the cellular IPS protein contains an NS3/4A cleavage site, HCV infection of these cells results in NS3 cleavage of the fusion protein from the mitochondrial membrane resulting in relocalization of the fluorescent protein from the cytoplasm to the cell nucleus¹⁰⁴. These types of reporter cell lines are particularly useful for monitoring initial infection events, but perhaps could also be adapted for monitoring the inhibition of steady-state (i.e. chronic) infection depending on the stability of the signal molecule used.

5.2 High throughput compound screening

As noted above, well before cell-based HCV model systems were available efforts were made to produce active forms of the HCV-encoded NS3 protease and NS5B polymerase to screen for inhibitors. However, since the development of cell-based HCV model systems, the bulk of HCV drug discovery has turned to cell-based high throughput screening (HTS). Traditionally, HTS involves large collections (i.e. libraries) of compounds to identify those that exhibit antiviral activity and thus could potentially be developed into clinically useful therapeutic drugs. Notably, all the cell-based HCV experimental systems described above have been adapted and successfully used for high throughput compound screening

5.3 Reporter gene based screening

Several high throughput luciferase-based HCVpp entry screens^{61, 62, 105} as well as replicon replication screens have been reported^{92, 106, 107} and clearly provide a robust approach for identifying inhibitors against the specific aspects of HCV infection recapitulated by these systems. However, this approach is more problematic in the context of the full infection system due to the significantly lower titers that can be achieved with viral constructs after the insertion of the reporter gene, which significantly limits the ability to create the high titer

viral stocks required. Additionally, with reporter gene assays, one has to be cognizant of false positive hits that result when compounds directly inhibit the reporter gene assay.

5.4 HCV NS3 as a reporter gene

As an alternative HTS approach, other groups have opted to use the viral NS3 protease as an innately encoded reporter gene. This has the advantage of not requiring deleterious manipulation of the viral genome (i.e. insertion of foreign reporter gene sequences) and avoids the issue of identifying irrelevant reporter gene inhibitors. As described above, three groups have stably integrated NS3 cleavable reporter gene fusions into Huh7 cells such that a detectable signal is observed upon infection of the cell. Boyle et al (2005)¹⁰⁸ and Yu et al (2009)¹⁰⁹ developed more traditional mix-and-measure fluorescence resonance energy transfer (FRET)-based assays that uses NS3 protease activity as quantitative read out for HCV levels in the replicon system and HCVcc infection system, respectively. The approach consists of using a peptide substrate containing the HCV NS3 peptide cleavage sequence flanked on either side with fluorophores that quench each other when they are in close proximity on the intact peptide. Replicon cells or infected cells are first incubated in the presence or absence of compounds from a library. After a period of time is allotted for potential inhibitory activity, cells are lysed and level of HCV in the cells is then quantitatively detected by adding the NS3 substrate peptide to the cell lysate and measuring the fluorescence generated when NS3 cleaves the substrate.

5.5 High throughput siRNA library screens

Compound library screening has long been a staple of drug discovery, but the same high throughput approaches are now also routinely used to screen genomic siRNA libraries to identify host cell factors that are required for viral infection. In terms of drug discovery, the concept behind functional siRNA screening is the identification of useful drug targets rather than screening directly for potential inhibitors. An advantage of this approach is that it is likely that all HCV genotypes interact with the same host cell factors and thus cellular targets might be more broadly effective. Additionally, host cell targets typically exhibit a higher barrier to the development of resistance. The challenge after an RNAi screen is to either design an inhibitor that specifically blocks the viral interaction with the necessary host cell protein or focus on host factors that are transiently dispensable for host cell function but absolutely critical for the virus life cycle. Recent examples of potential HCV antiviral targets originally identified via siRNA screening are EGFR and EphA2⁸⁵, which highlights the utility of the approach in general. One curiosity associated with these high throughput siRNA screens however is the variability in the genes identified by different groups. Presumably at least some of the differences are due to diverse siRNA chemistries, efficacies, and off target effects combined with different assay endpoints, cell types, virus preps, and filtering parameters, but it is still surprising how little overlap (<10%) at individual genes level has been observed. Future comparisons of results across studies with a focus on biological process/pathways might help to provide more insight into the large amount of information being generated by these studies.

6 Expert opinion

Although acute HCV infection rates have declined over the years, a large chronically HCV-infected cohort is progressing to cirrhosis and is at risk for hepatocellular carcinoma and hepatic decompensation. Hence, now more than ever, there is an urgent need to develop effective therapeutics that can clear chronic HCV infection. For decades, slow progress in the HCV research field has left us clinically dependent on sub-optimally effective and difficult to tolerate interferon and ribavirin based therapies. Significant advances in HCV experimental model development (e.g. HCV replicons, HCVpp, the HCVcc infection

system) and innovations in high throughput screening have ushered in a new era of discovery that has expedited HCV drug development and provided new hope that chronic HCV will ultimately be a “curable” disease. However, it is imperative that we continue to rapidly reach for the goal of developing interferon-free, broad spectrum HCV treatment regimens that are affordable, well-tolerated and effective in all patients and against all genotypes.

A number of advances are needed to further facilitate HCV drug discovery. Perhaps at the top of that list would be a robust cell culture system permissive to infection by all HCV genotypes as this would allow for the identification of more broadly effective inhibitors or at least a panel of inhibitors optimized for specific genotypes. Closer to the clinic, the ability to study the drug sensitivity and viral escape patterns of clinical isolates in vitro might additionally allow for preliminary efficacy testing, providing means to individualize therapy in more difficult to treat patients. Notably, while such ideal systems may be years in the making, it is important to realize that the insights about key viral-host interactions gained during the process of developing these more physiologically relevant in vitro and in vivo model systems will continue to bring us closer to achieving our drug development goals.

While this review focuses on the tangible bench top tools and screening strategies that have led to and continue to feed the current richly populated HCV drug development pipeline, it is relevant to note that systems biology approaches will also continue to be central in promoting the rapid creation and translation of new knowledge into practical use in the clinic. For example, mathematical modeling of HCV inhibition kinetics under treatment has played a major role in evaluating, understanding and even directing HCV treatment in the clinic. Current in vitro and in vivo modeling efforts are further elucidating the complex mechanism of action of different HCV antiviral agents. In the future, the use of in silico simulations based on these models should prove valuable for efficiently predicting optimal synergistic therapeutic combinations that minimize viral escape. Likewise, advances in sequencing and genomic analysis are allowing in-depth characterization of host and viral genomic differences, which should also allow for a more informed understanding of the antiviral potential of specific drugs in different clinical situations. Of course ultimately, the final challenge will be accessibility and affordability of care, but presumably the more successful we are in developing a diverse array of effective clinical therapeutic options, the more likely this issue will be easier to overcome.

References

1. Alter MJ. Epidemiology of hepatitis C virus infection. *World J Gastroenterol*. 2007 May 7; 13(17): 2436–2441. [PubMed: 17552026]
2. Hoofnagle JH. Course and outcome of hepatitis C. *Hepatology*. 2002 Nov; 36(5 Suppl 1):S21–S29. [PubMed: 12407573]
3. Seeff LB. Natural history of chronic hepatitis C. *Hepatology*. 2002 Nov; 36(5 Suppl 1):S35–S46. [PubMed: 12407575]
4. Willems M, Metselaar HJ, Tilanus HW, et al. Liver transplantation and hepatitis C. *Transpl Int*. 2002 Mar; 15(2–3):61–72. [PubMed: 11935162]
5. McHutchison JG. Understanding hepatitis C. *Am J Manag Care*. 2004 Mar; 10(2 Suppl):S21–S29. [PubMed: 15084064]
6. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. *Hepatology*. 2011 Oct; 54(4):1433–1444. [PubMed: 21898493]
7. Tencate V, Sainz B Jr, Cotler SJ, Uprichard SL. Potential treatment options and future research to increase hepatitis C virus treatment response rate. *Hepat Med*. Oct; 2010(2):125–145. [PubMed:

21331152] * This is a review detailing HCV antiviral agents currently in the clinical testing pipeline.

8. Suzuki T, Aizaki H, Murakami K, et al. Molecular biology of hepatitis C virus. *J Gastroenterol*. 2007 Jun; 42(6):411–423. [PubMed: 17671755]
9. Suzuki T, Ishii K, Aizaki H, Wakita T. Hepatitis C viral life cycle. *Adv Drug Deliv Rev*. 2007 Oct 10; 59(12):1200–1212. [PubMed: 17825945]
10. Poenisch M, Bartenschlager R. New insights into structure and replication of the hepatitis C virus and clinical implications. *Semin Liver Dis*. 2012 Nov; 30(4):333–347. [PubMed: 20960374]
11. Popescu CI, Dubuisson J. Role of lipid metabolism in hepatitis C virus assembly and entry. *Biol Cell*. 2009 Jan; 102(1):63–74. [PubMed: 19857204]
12. Bartenschlager R, Penin F, Lohmann V, Andre P. Assembly of infectious hepatitis C virus particles. *Trends Microbiol*. 2011 Feb; 19(2):95–103. [PubMed: 21146993]
13. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. *Science*. 2005 Jul 22; 309(5734):623–626. [PubMed: 15947137] ** This is one of three papers reporting the development of the cell culture HCV infection system (HCVcc)
14. Zhong J, Gastaminza P, Chung J, et al. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. *J Virol*. 2006 Nov; 80(22):11082–11093. [PubMed: 16956932]
15. Haid S, Pietschmann T, Pecheur EI. Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. *J Biol Chem*. 2009 Jun 26; 284(26):17657–17667. [PubMed: 19411248]
16. Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. *J Hepatol*. 2011 Mar; 54(3):566–576. [PubMed: 21146244]
17. Sainz B Jr, Barretto N, Martin DN, et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. *Nat Med*. 2012; 18(2):281–285. [PubMed: 22231557]
18. Meertens L, Bertaux C, Dragic T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. *J Virol*. 2006 Dec; 80(23):11571–11578. [PubMed: 17005647]
19. Lavillette D, Bartosch B, Nourrisson D, et al. Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes. *J Biol Chem*. 2006 Feb 17; 281(7):3909–3917. [PubMed: 16356932]
20. Blanchard E, Belouzard S, Goueslain L, et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. *J Virol*. 2006 Jul; 80(14):6964–6972. [PubMed: 16809302]
21. Hsu M, Zhang J, Flint M, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. *Proc Natl Acad Sci U S A*. 2003 Jun 10; 100(12):7271–7276. [PubMed: 12761383] * One of two papers, first describing the HCVpp system and documenting HCVgp-dependent viral entry.
22. Tscherne DM, Jones CT, Evans MJ, et al. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. *J Virol*. 2006 Feb; 80(4):1734–1741. [PubMed: 16439530]
23. Tang H, Grise H. Cellular and molecular biology of HCV infection and hepatitis. *Clin Sci (Lond)*. 2009 Jul; 117(2):49–65. [PubMed: 19515018]
24. Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science*. 1999 Jul 2; 285(5424):110–113. [PubMed: 10390360] ** Paper reporting the first HCV subgenomic replicon, a system that has been critical to the advancement of HCV drug discovery.
25. Lindenbach, BD.; L. Tellinghuisen, T.; Raney, KD., et al. Replication Viral Genome Replication. US: Springer; 2009. Hepatitis C Virus Genome; p. 61–88.
26. Gastaminza P, Cheng G, Wieland S, et al. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. *J Virol*. 2008 Mar; 82(5):2120–2129. [PubMed: 18077707]
27. Piver E, Roingeard P, Pages JC. The cell biology of hepatitis C virus (HCV) lipid addiction: molecular mechanisms and its potential importance in the clinic. *Int J Biochem Cell Biol*. 2010 Jun; 42(6):869–879. [PubMed: 20067842]

28. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science*. 1989 Apr 21; 244(4902):359–362. [PubMed: 2523562] ** Paper reporting the cloning of the first HCV genome.
29. Taliani M, Bianchi E, Narjes F, et al. A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates. *Anal Biochem*. 1996 Aug 15; 240(1):60–67. [PubMed: 8811880]
30. Zhang R, Beyer BM, Durkin J, et al. A continuous spectrophotometric assay for the hepatitis C virus serine protease. *Anal Biochem*. 1999 Jun 1; 270(2):268–275. [PubMed: 10334844]
31. Kyono K, Miyashiro M, Taguchi I. Detection of hepatitis C virus helicase activity using the scintillation proximity assay system. *Anal Biochem*. 1998 Mar 15; 257(2):120–126. [PubMed: 9514793]
32. Kyono K, Miyashiro M, Taguchi I. Expression and purification of a hepatitis C virus NS3/4A complex, and characterization of its helicase activity with the Scintillation Proximity Assay system. *J Biochem*. 2004 Feb; 135(2):245–252. [PubMed: 15047727]
33. Hagedorn CH, van Beers EH, De Staercke C. Hepatitis C virus RNA-dependent RNA polymerase (NS5B polymerase). *Curr Top Microbiol Immunol*. 2000; 242:225–260. [PubMed: 10592663]
34. Leveque VJ, Wang QM. RNA-dependent RNA polymerase encoded by hepatitis C virus: biomedical applications. *Cell Mol Life Sci*. 2002 Jun; 59(6):909–919. [PubMed: 12169021]
35. Bartenschlager R. Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture. *Curr Opin Microbiol*. 2006 Aug; 9(4):416–422. [PubMed: 16814596]
36. Neyts J. Selective inhibitors of hepatitis C virus replication. *Antiviral Res*. 2006 Sep; 71(2–3):363–371. [PubMed: 16843538]
37. Horscroft N, Lai VC, Cheney W, et al. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus. *Antivir Chem Chemother*. 2005; 16(1):1–12. [PubMed: 15739617]
38. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. *J Exp Med*. 2003 Mar 3; 197(5):633–642. [PubMed: 12615904] * One of two papers, first describing the HCVpp system and documenting HCVgp-dependent viral entry.
39. McKeating JA, Zhang LQ, Logvinoff C, et al. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. *J Virol*. 2004 Aug; 78(16):8496–8505. [PubMed: 15280458]
40. Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. *Proc Natl Acad Sci U S A*. 2005 Jun 28; 102(26):9294–9299. [PubMed: 15939869] ** One of three papers reporting the development of the cell culture HCV infection system (HCVcc).
41. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat Med*. 2005 Jul; 11(7):791–796. [PubMed: 15951748] ** One of three papers reporting the development of the cell culture HCV infection system (HCVcc)
42. Ikeda M, Abe K, Dansako H, et al. Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. *Biochem Biophys Res Commun*. 2005 Apr 22; 329(4):1350–1359. [PubMed: 15766575]
43. Maekawa S, Enomoto N, Sakamoto N, et al. Introduction of NS5A mutations enables subgenomic HCV replicon derived from chimpanzee-infectious HC-J4 isolate to replicate efficiently in Huh-7 cells. *J Viral Hepat*. 2004 Sep; 11(5):394–403. [PubMed: 15357644]
44. Kato T, Date T, Miyamoto M, et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. *Gastroenterology*. 2003 Dec; 125(6):1808–1817. [PubMed: 14724833]
45. Kishine H, Sugiyama K, Hijikata M, et al. Subgenomic replicon derived from a cell line infected with the hepatitis C virus. *Biochem Biophys Res Commun*. 2002 May 10; 293(3):993–999. [PubMed: 12051758]
46. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. *J Virol*. 2003 Mar; 77(5):3181–3190. [PubMed: 12584342]
47. Ikeda M, Yi M, Li K, Lemon SM. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. *J Virol*. 2002 Mar; 76(6):2997–3006. [PubMed: 11861865]

48. Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. *J Virol*. 2001 Sep; 75(18):8516–8523. [PubMed: 11507197]
49. Date T, Kato T, Miyamoto M, et al. Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. *J Biol Chem*. 2004 May 21; 279(21):22371–22376. [PubMed: 14990575]
50. Kato T, Date T, Miyamoto M, et al. Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. *J Virol*. 2005 Jan; 79(1):592–596. [PubMed: 15596851]
51. Ali S, Pellerin C, Lamarre D, Kukolj G. Hepatitis C virus subgenomic replicons in the human embryonic kidney 293 cell line. *J Virol*. 2004 Jan; 78(1):491–501. [PubMed: 14671129]
52. Zhu Q, Guo JT, Seeger C. Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. *J Virol*. 2003 Sep; 77(17):9204–9210. [PubMed: 12915536]
53. Uprichard SL, Chung J, Chisari FV, Wakita T. Replication of a hepatitis C virus replicon clone in mouse cells. *Virology*. 2006; 3:89. [PubMed: 17069661]
54. Bukh J, Pietschmann T, Lohmann V, et al. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. *Proc Natl Acad Sci U S A*. 2002 Oct 29; 99(22):14416–14421. [PubMed: 12391335]
55. Ploss A, Evans MJ, Gaysinskaya VA, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. *Nature*. 2009 Feb 12; 457(7231):882–886. [PubMed: 19182773]
56. Evans MJ, von Hahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. *Nature*. 2007 Apr 12; 446(7137):801–805. [PubMed: 17325668]
57. Owsianka A, Tarr AW, Juttla VS, et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. *J Virol*. 2005 Sep; 79(17):11095–11104. [PubMed: 16103160]
58. Tong Y, Zhu Y, Xia X, et al. Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. *J Virol*. 2011 Mar; 85(6):2793–2802. [PubMed: 21177818]
59. Brown KS, Keogh MJ, Owsianka AM, et al. Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. *Protein Cell*. 2010 Jul; 1(7):664–674. [PubMed: 21203938]
60. Meuleman P, Albecka A, Belouzard S, et al. Griffithsin has antiviral activity against hepatitis C virus. *Antimicrob Agents Chemother*. 2011 Nov; 55(11):5159–5167. [PubMed: 21896910]
61. Wong-Staal F, Syder AJ, McKelvy JF. Targeting HCV entry for development of therapeutics. *Viruses*. 2010 Aug; 2(8):1718–1733. [PubMed: 21994703]
62. Yang JP, Zhou D, Wong-Staal F. Screening of small-molecule compounds as inhibitors of HCV entry. *Methods Mol Biol*. 2009; 510:295–304. [PubMed: 19009270]
63. Molina S, Castet V, Fournier-Wirth C, et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. *J Hepatol*. 2007 Mar; 46(3):411–419. [PubMed: 17156886]
64. Kato T, Furusaka A, Miyamoto M, et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. *J Med Virol*. 2001 Jul; 64(3):334–339. [PubMed: 11424123] * Paper reporting the cloning of the JFH-1 infectious clone.
65. Lindenbach BD, Meuleman P, Ploss A, et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. *Proc Natl Acad Sci U S A*. 2006 Mar 7; 103(10):3805–3809. [PubMed: 16484368]
66. Cai Z, Zhang C, Chang KS, et al. Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. *J Virol*. 2005 Nov; 79(22):13963–13973. [PubMed: 16254332]
67. Scheel TK, Gottwein JM, Mikkelsen LS, et al. Recombinant HCV variants with NS5A from genotypes 1–7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. *Gastroenterology*. 2011 Mar; 140(3):1032–1042. [PubMed: 21111742]
68. Li YP, Ramirez S, Gottwein JM, Bukh J. Non-genotype-specific role of the hepatitis C virus 5' untranslated region in virus production and in inhibition by interferon. *Virology*. 2011 Dec 20; 421(2):222–234. [PubMed: 22029937]

69. Gottwein JM, Scheel TK, Jensen TB, et al. Development and characterization of hepatitis C virus genotype 1–7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. *Hepatology*. 2009 Feb; 49(2):364–377. [PubMed: 19148942]
70. Gottwein JM, Jensen TB, Mathiesen CK, et al. Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A. *J Virol*. 2011 Sep; 85(17):8913–8928. [PubMed: 21697486]
71. Pietschmann T, Kaul A, Koutsoudakis G, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. *Proc Natl Acad Sci U S A*. 2006 May 9; 103(19):7408–7413. [PubMed: 16651538]
72. Kato T, Matsumura T, Heller T, et al. Production of infectious hepatitis C virus of various genotypes in cell cultures. *J Virol*. 2007 May; 81(9):4405–4411. [PubMed: 17301131]
73. Pietschmann T, Zayas M, Meuleman P, et al. Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. *PLoS Pathog*. 2009 Jun. 5(6):e1000475. [PubMed: 19521536]
74. Yi M, Villanueva RA, Thomas DL, et al. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. *Proc Natl Acad Sci U S A*. 2006 Feb 14; 103(7):2310–2315. [PubMed: 16461899]
75. Molina S, Castet V, Pichard-Garcia L, et al. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. *J Virol*. 2008 Jan; 82(1):569–574. [PubMed: 17942559]
76. Buck M. Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. *PLoS One*. 2008; 3(7):e2660. [PubMed: 18628977]
This article described a promising primary human hepatocyte culture system, permissible to infection with naturally occurring HCV genotypes 1, 2, 3 and 4 clinical isolates.
77. Sheahan T, Jones CT, Ploss A. Advances and challenges in studying hepatitis C virus in its native environment. *Expert Rev Gastroenterol Hepatol*. 2010 Oct; 4(5):541–550. [PubMed: 20932139]
78. Ploss A, Khetani SR, Jones CT, et al. Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. *Proc Natl Acad Sci U S A*. Feb 16; 107(7):3141–3145. [PubMed: 20133632]
79. Ploss A, Rice CM. Towards a small animal model for hepatitis C. *EMBO Rep*. 2009 Nov; 10(11):1220–1227. [PubMed: 19834510]
80. Dandri M, Burda MR, Torok E, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. *Hepatology*. 2001 Apr; 33(4):981–988. [PubMed: 11283864]
81. Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. *Nat Med*. 2001 Aug; 7(8):927–933. [PubMed: 11479625] ** Article reporting the first murine model suitable for studying hepatitis C virus infection in vivo.
82. Meuleman P, Hesselgesser J, Paulson M, et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. *Hepatology*. 2008 Dec; 48(6):1761–1768. [PubMed: 19030166]
83. Vanwolleghem T, Bukh J, Meuleman P, et al. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. *Hepatology*. 2008 Jun; 47(6):1846–1855. [PubMed: 18452146]
84. Kneteman NM, Mercer DF. Mice with chimeric human livers: who says supermodels have to be tall? *Hepatology*. 2005 Apr; 41(4):703–706. [PubMed: 15789361]
85. Lupberger J, Zeisel MB, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. *Nat Med*. 2011 May; 17(5):589–595. [PubMed: 21516087]
86. Lacek K, Vercauteren K, Grzyb K, et al. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. *J Hepatol*. 2012 Mar 10. [Epub ahead of print].
87. Dorner M, Horwitz JA, Robbins JB, et al. A genetically humanized mouse model for hepatitis C virus infection. *Nature*. 2011 Jun 9; 474(7350):208–211. [PubMed: 21654804] * Report that describes evidence of HCV entry into hepatocytes of transgenic mice expressing 4 human HCV receptors (CD81, SRB1, Claudin1 and occludin).

88. Lin LT, Noyce RS, Pham TN, et al. Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122. *J Virol*. 2010 Sep; 84(18):9170–9180. [PubMed: 20592082]
89. Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. *J Virol*. 2001 May; 75(10):4614–4624. [PubMed: 11312331]
90. Lohmann V, Korner F, Dobierzewska A, Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. *J Virol*. 2001 Feb; 75(3):1437–1449. [PubMed: 11152517]
91. Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. *J Virol*. 2002 Dec; 76(24):13001–13014. [PubMed: 12438626]
92. Bartenschlager R. Hepatitis C virus replicons: potential role for drug development. *Nat Rev Drug Discov*. 2002 Nov; 1(11):911–916. [PubMed: 12415250]
93. Murray EM, Grobler JA, Markel EJ, et al. Persistent replication of hepatitis C virus replicons expressing the beta-lactamase reporter in subpopulations of highly permissive Huh7 cells. *J Virol*. 2003 Mar; 77(5):2928–2935. [PubMed: 12584317]
94. Zuck P, Murray EM, Stec E, et al. A cell-based beta-lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication. *Anal Biochem*. 2004 Nov 15; 334(2):344–355. [PubMed: 15494142]
95. Moradpour D, Evans MJ, Gosert R, et al. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. *J Virol*. 2004 Jul; 78(14):7400–7409. [PubMed: 15220413]
96. Yi M, Bodola F, Lemon SM. Subgenomic hepatitis C virus replicons inducing expression of a secreted enzymatic reporter protein. *Virology*. 2002 Dec 20; 304(2):197–210. [PubMed: 12504562]
97. Kamada K, Shoji I, Deng L, et al. Generation of a recombinant reporter hepatitis C virus useful for the analyses of virus entry, intra-cellular replication and virion production. *Microbes Infect*. 2011 Jan; 14(1):69–78. [PubMed: 21917232]
98. Wu Y, Liao Q, Yang R, et al. A novel luciferase and GFP dual reporter virus for rapid and convenient evaluation of hepatitis C virus replication. *Virus Res*. 2011 Feb; 155(2):406–414. [PubMed: 21144873]
99. Jones CT, Murray CL, Eastman DK, et al. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. *J Virol*. 2007 Aug; 81(16):8374–8383. [PubMed: 17537845]
100. Koutsoudakis G, Kaul A, Steinmann E, et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. *J Virol*. 2006 Jun; 80(11):5308–5320. [PubMed: 16699011]
101. Iro M, Witteveldt J, Angus AG, et al. A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. *Antiviral Res*. 2009 Aug; 83(2):148–155. [PubMed: 19397930]
102. Chen Z, Simeon RL, Chockalingam K, Rice CM. Creation and characterization of a cell-death reporter cell line for hepatitis C virus infection. *Antiviral Res*. 2010 May; 86(2):220–223. [PubMed: 20188762]
103. Chockalingam K, Simeon RL, Rice CM, Chen Z. A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. *Proc Natl Acad Sci U S A*. 2009 Feb 23; 107(8):3764–3769. [PubMed: 20142494]
104. Jones CT, Catanese MT, Law LM, et al. Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. *Nat Biotechnol*. 2010 Feb; 28(2):167–171. [PubMed: 20118917]
105. Coburn GA, Fisch DN, Moorji SM, et al. Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture. *PLoS One*. 2012; 7(4):e35351. [PubMed: 22545104]
106. Mondal R, Koev G, Pilot-Matias T, et al. Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well. *Antiviral Res*. 2009 Apr; 82(1):82–88. [PubMed: 19174175]

107. Robinson M, Yang H, Sun SC, et al. Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a. *Antimicrob Agents Chemother.* 2010 Aug; 54(8):3099–3106. [PubMed: 20516274]
108. O'Boyle DR 2nd, Nower PT, Lemm JA, et al. Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay. *Antimicrob Agents Chemother.* 2005 Apr; 49(4):1346–1353. [PubMed: 15793110]
109. Yu X, Sainz B Jr, Uprichard SL. Development of a cell-based hepatitis C virus infection fluorescent resonance energy transfer assay for high-throughput antiviral compound screening. *Antimicrob Agents Chemother.* 2009 Oct; 53(10):4311–4319. [PubMed: 19620334]

Article highlights box

- New HCV infection rates have decreased, but there is a rapidly growing public health burden of liver disease, including hepatocellular carcinoma, from those who are chronically infected. Hence, there is an urgent need to develop broad spectrum HCV treatment regimens that are affordable, well-tolerated and effective in all patients and against all genotypes.
- Although research efforts have been hindered in the past due to the lack of suitable HCV experimental models, the development of several robust cell-based systems, particularly the first HCV cell culture infection system (HCVcc) has expedited HCV drug discovery.
- Despite the incredible advances in HCV model development, critical limitations of the current experimental systems exist and continued efforts to attain more physiologically relevant in vitro and in vivo models permissive to infection by all HCV genotypes and clinical isolates are needed.
- Creative innovations in simple, rapid, and sensitive HCV detection methods have contributed to the effective adaptation of emerging HCV experimental models for high throughput antiviral screening.
- With the advent of RNAi technology, high throughput screening of host factors involved in HCV infection has become a new and effective means of identifying potential host cell antiviral targets that may prove useful for broadly inhibiting HCV infection of all genotypes while additionally minimizing the rapid viral escape that can occur when drugs are targeted to specific residues within individual viral proteins.